Reports / Nephrology Reports / Market Dynamix: Diabetic Nephropathy US
Market Dynamix™: Diabetic Nephropathy US
Diabetic kidney disease (DKD) affects millions of Americans and is the leading cause of end stage renal disease (ESRD). Several promising agents such as Reata’s bardoxolone have failed to succeed in clinical trials. Physicians routinely place the need for new drugs to treat this condition as a high priority and there are several late stage clinical trials in process.
Market Dynamix™: Diabetic Nephropathy (US) combines qualitative feedback from leading opinion leaders and other stakeholders with large scale quantitative feedback of “in the trenches” nephrologists, endocrinologists and PCPs. Additional interviews with payers provide insight into programs and strategies aimed at pre-diabetes, diabetes and diabetic nephropathy.
Qualitative interviews with peer-nominated anemia KOLs (n=5) will describe the new therapies on the horizon and their perspective on where each will have an advantage. Additional interviews with nephrologists (n=5), endocrinologists (n=5) and PCPs (n=5) give real world perspective on the challenge of managing this condition.
An on-line quantitative survey of office-based nephrologists (n=75), endocrinologists (n=75) and primary care physicians (n=75) addresses patient load, referral and co-management issues, current treatment approaches, unmet needs and reaction to pipeline product profiles. This is the second report published on this topic; a prior report was published in 2016.
Learn more about Market Dynamix™ reports here.
- What is the comparative level of unmet need for new products to treat diabetic kidney disease?
- How do physicians assess DKD and what do referral patterns look like between PCPs, endocrinologists and nephrologists? Which lab tests and target levels are used to guide treatment and referral decisions?
- Which medications are used in an attempt to slow DKD and how satisfied are physicians with these treatments? Do physicians preferentially use canagliflozin (and/or other SGLT2 inhibitors) in patients with DKD on the basis of its current trial (CREDENCE) and efficacy in T2D?
- Regarding new treatments, what is the level of unmet need? What products are physicians aware of? What unique features are most appealing and most worrisome?
- How do physicians respond to pipeline product profiles for canagliflozin, finerenone, CCX-140, bardoxolone methyl, praliciguat, TMX-049, and Neo-kidney augmentation?
Canagliflozin (Janssen), Finerenone (Bayer), CCX-140 (ChemoCentryx), TMX-049 (Tiejin Pharmaceuticals), Praliciguat (Ironwood), Bardoxolone methyl (Reata), Neo-kidney augmentation (InRegen)*
*List not inclusive of all
Pfizer’s Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market – July 31, 2018
Amgen’s Parsabiv Doubles in Most Recent Quarter But Strict Usage Guidelines from Large Dialysis Organizations, DaVita and Fresenius Medical Care, Stifle Potential – July 24, 2018